Compound: ETHAMIVAN
SMILES: O=C(N(CC)CC)c1cc(OC)c(O)cc1
InChIKey: BQJODPIMMWWMFC-UHFFFAOYSA-N
Synonyms: ETHAMIVAN, Etamivan, 304-84-7, Vandid, Emivan, Etamivanum, N,N-Diethylvanillamide, N,N-Diethyl-4-hydroxy-3-methoxybenzamide, Benzamide, N,N-diethyl-4-hydroxy-3-methoxy-, NSC-406087, Clairvan, M44O63YPV9, DTXSID3023007, CHEBI:92675, NSC406087, DTXCID103007, RefChem:591359, R07AB04, 206-157-3, Vanillic acid diethylamide, Analepticon, Simaron, Cardiovanil, Corivanil, Diethamivan, Ventilone, Romecor, Sevanil, Diethylvanillamide, Cardiovamil, Sevinal, Diethylamide de vanillique, Vanillic acid N,N-diethylamide, Vanillinsaeure-diaethylamid, Vanillamide, N,N-diethyl-, 3-Methoxy-4-hydroxybenzoic acid diethylamide, Etamivan [INN], N,N-diethyl-4-hydroxy-3-methoxy-benzamide, MLS000028445, Ethamivan;N,N-Diethylvanillamide, 2-METHYL-4-DIETHYLAMIDE-PHENOL, NCGC00015397-02, NCGC00015397-06, CAS-304-84-7, SMR000058359, Etamivanum [INN-Latin], N,N-diethyl(4-hydroxy-3-methoxyphenyl)carboxamide, SR-01000003047, Ethamivan [USAN:USP], Vanillinsaeure-diaethylamid [German], EINECS 206-157-3, NSC 406087, BRN 2694478, UNII-M44O63YPV9, AI3-20163, 2xdl, Prestwick_909, Vandid (TN), Vanillamide,N-diethyl-, Opera_ID_522, ETHAMIVAN [MI], Ethamivan (USAN/INN), ETHAMIVAN [USAN], Prestwick0_000500, Prestwick1_000500, Prestwick2_000500, Prestwick3_000500, Lopac-E-0137, ETAMIVAN [MART.], Epitope ID:768765, ETAMIVAN [WHO-DD], Lopac0_000459, BSPBio_000399, 4-10-00-01481 (Beilstein Handbook Reference), MLS001146918, SCHEMBL119823, SPBio_002320, BPBio1_000439, orb2893747, CHEMBL1229908, SCHEMBL29351657, vanillic acid N,N-diethyl amide, HMS1569D21, HMS2094A19, HMS2096D21, HMS2231D12, HMS3261K20, HMS3369J14, HMS3713D21, Pharmakon1600-01505994, HY-B1096, Tox21_110135, Tox21_110136, Tox21_500459, WLN: 2N2 & VR DQ CO1, BDBM50482752, EBC-13945, MFCD00026727, NSC759302, SBB057405, AKOS003382844, Tox21_110135_1, CCG-204551, CS-4684, DB08989, LP00459, NSC-759302, SDCCGSBI-0050444.P003, NCGC00015397-01, NCGC00015397-03, NCGC00015397-04, NCGC00015397-05, NCGC00015397-07, NCGC00015397-08, NCGC00015397-10, NCGC00015397-15, NCGC00023704-03, NCGC00023704-04, NCGC00261144-01, BP-12587, MS-23252, Benzamide,N-diethyl-4-hydroxy-3-methoxy-, SBI-0050444.P002, DB-047788, EU-0100459, N,N-Diethyl-4-hydroxy-3-methoxybenzamide #, NS00002944, ST45025689, N,N-diethyl-4-hydroxy-3-(methyloxy)benzamide, D04080, E 0137, F85239, EN300-7522809, Q5402414, SR-01000003047-2, SR-01000003047-5, BRD-K38055836-001-03-9, BRD-K38055836-001-21-1, 2DL
Theoretical properties:
molecular_formula: C12H17NO3
molecular_weight: 223.27 g/mol
exact_mass: 223.12084340 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 4
heavy_atom_count: 16
topological_polar_surface_area: 49.8 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 95-95.5
solubility: >33.5 [ug/mL] (The mean of the results at pH 7.4)
Descriptions:
pubchem: Etamivan is phenol substituted at C-2 and C-4 by a methoxy group and an N,N-diethylaminocarbonyl group respectively. A respiratory stimulant drug related to nikethamide, it has now fallen largely into disuse. It is a member of phenols and a member of methoxybenzenes.
chebi: Phenol substituted at C-2 and C-4 by a methoxy group and an <em>N</em>,<em>N</em>-diethylaminocarbonyl group respectively. A respiratory stimulant drug related to nikethamide, it has now fallen largely into disuse.
chembl: ETHAMIVAN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.
wikipedia: Etamivan (INN, or ethamivan (USAN); trade names Analepticon, Emivan, and Vandid) is a respiratory stimulant drug related to nikethamide. It was mainly used in the treatment of barbiturate overdose and chronic obstructive pulmonary disease, but has now largely fallen into disuse.
Adverse effects which are common to the respiratory stimulant class include sneezing, coughing, and laryngospasm when infused too rapidly. More serious adverse events include muscle twitching, tremors, and convulsions. The dose to treat barbiturate intoxication or carbon dioxide narcosis in adults ranges from 0.5 mg/kg to 5.0 mg/kg, infused intravenously over several minutes. Epilepsy and the use of monoamine oxidase inhibitors or other adrenergic drugs are contraindications.